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Purpose: To describe the clinical and genetic characteristics of a Japanese family in 
which one member exhibited Bietti’s crystalline corneoretinal dystrophy (BCD).  
Methods: Using direct sequencing, mutation screening was performed in the CYP4V2 
gene of both the patient with BCD and her daughter. Ophthalmic examinations were 
performed to determine the clinical features of both subjects.  
Results: The 64-year-old female patient had a bilateral visual acuity of 0.4. Slit lamp 
examination revealed bilateral crystalline-like deposits at the superior limbus of the 
cornea. Fundus examination revealed there was chorioretinal atrophy along with 
numerous glistening yellowish-white crystalline deposits that were scattered throughout 
the posterior pole and the mid-peripheral retina. Standard flash electroretinography 
showed an extinguished electroretinogram and Goldmann kinetic perimetry detected a 
relative scotoma. Genetic analysis revealed that the patient had a heterozygous mutation 
in the CYP4V2 gene (IVS6–8delTCATACAGGTCATCGCG/GC), which is the most commonly 
found mutation in Japanese patients with BCD. Furthermore, the patient was also shown 
to have a novel heterozygous point mutation in exon 9 of the CYP4V2 gene (c.1168C>T). 
In contrast, her daughter exhibited no clinical findings for BCD even though she carried 
the same heterozygous mutation in the CYP4V2 gene (c.1168C>T).  Case Rep Ophthalmol 2011;2:296–301 
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Conclusion: A novel compound heterozygous mutation was found in the CYP4V2 gene of 
a patient with BCD. This previously unreported c.1168C>T mutation causes a missense 
mutation (p.R390C) in the CYP4V2 protein. 
 
Introduction 
Bietti’s crystalline corneoretinal dystrophy (BCD, MIM 210370) is characterized by an 
autosomal recessive form of progressive chorioretinal degeneration that is associated with 
numerous crystal deposits in the posterior portion of the retina and peripheral area of the 
corneal stroma [1]. The disease is known to be caused by mutations in the CYP4V2 gene 
(HGNC: 23198) [2]. While the protein product of the CYP4V2 gene is a member of the 
cytochrome p-450 family, CYP4 enzymes, it is generally accepted that these products play 
a role in lipid metabolism [2, 3]. It has been recently reported that CYP4V2 is a selective 
omega-hydroxylase of saturated medium-chain fatty acids, in addition to having a 
relatively high catalytic efficiency toward myristic acid [4]. Nevertheless, the exact 
mechanism by which the chorioretinal degeneration is able to deposit crystal materials in 
the retina, cornea, conjunctival fibroblasts and lymphocytes remains unknown [5, 6]. 
While homozygous mutations of IVS6–8delTCATACAGGTCATC/insGC (c.802–8 
810del17insGC (Exon7del)) in the CYP4V2 gene are commonly found in Japanese 
patients with BCD, they are also found in both Chinese and Indonesian patients with 
BCD. To date, there have been approximately 31 mutations of the CYP4V2 gene reported 
[2, 7–11]. 
We recently discovered a case with a compound heterozygote for the CYP4V2 gene. 
This patient had mutations that were situated at exons 7 and 9. One of the mutations that 
have been found for exon 7 includes the above-mentioned IVS6–8delTCATACAGGTC-
ATC/insGC. The other mutation of exon 9 is p.R390C, which to the best of our 
knowledge, is a novel mutation that has yet to be reported. 
Methods 
For molecular genetic analysis, this study was conducted according to the tenets of the declaration of 
Helsinki and was approved by the Committee on Ethics of Hirosaki University Graduate School of 
Medicine. Mutation screening of the CYP4V2 gene was performed on both a patient with BCD and her 
daughter. After obtaining informed consent, genomic DNA was extracted from the peripheral blood 
leukocytes. The coding region (including the intron-exon boundary) of the CYP4V2 gene was amplified 
by polymerase chain reaction (PCR). The PCR products were analyzed using direct sequencing. To 
determine the clinical features that were present, both subjects underwent visual acuity, slit lamp, 
fundus, fluorescein angiography, Goldmann perimetry (GP) and electroretinography (ERG) 
examinations. 
Results 
The 64-year-old female patient had a bilateral visual acuity of 0.4. The slit lamp 
examination revealed bilateral crystalline-like deposits at the superior limbus of the 
cornea (fig. 1). The fundus examination revealed chorioretinal atrophy and numerous 
glistening yellowish-white crystalline deposits that were scattered throughout the Case Rep Ophthalmol 2011;2:296–301 
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posterior pole and the mid-peripheral retina (fig. 2). There were no deposits seen in the 
lens capsule. Full-field standard ERG showed there was an extinguished 
electroretinogram, and GP indicated the presence of relative scotoma. All these clinical 
findings indicated that this case had typical features of BCD. Genetic analysis revealed 
that the patient had a heterozygous mutation in the CYP4V2 gene (IVS6–8delTCATAC-
AGGTCATCGCG/GC), which is the most commonly found mutation in Japanese 
patients with BCD (fig. 3). Furthermore, this patient had a novel heterozygous mutation 
in the CYP4V2 gene (c.1168C>T, fig. 4). While her daughter, who has no clinical findings 
of BCD, exhibited the same heterozygous mutation in the CYP4V2 gene (c.1168C>T) in 
the exon 9, she lacked the IVS6–8delTCATACAGGTCATCGCG/GC mutation in the 
gene. 
Discussion 
BCD is a progressive chorioretinal degeneration that has been demonstrated to be 
caused by mutations in the CYP4V2 gene [2]. Although BCD phenotypes vary among 
patients, even when the same mutations are seen in a similar age group [8, 12], basic 
clinical findings including chorioretinal degeneration associated with crystalline deposits 
are common features [13]. 
The mutation of exon 7 (IVS6–8delTCATACAGGTCATCGCG/GC) has been 
commonly found not only in Japanese but also in Chinese and Indonesian patients with 
BCD [2, 7–13]. A molecular genetic study disclosed that this mutation breaks the splicing 
acceptor site of the exon 7, resulting in the skipping of exon 7 (Exon7del) [2]. As a result 
of this mutation, the translated protein is truncated and lacks peptides that are normally 
derived from the entire part of exon 7 [2]. It has been postulated that this truncated 
peptide causes a decreased fatty acid binding and removal of the cell attachment site [2]. 
We further speculated that there might be severe deterioration of the enzyme activity of 
the putative CYP4V2 protein, which is known as omega-hydroxylase. However, the 
molecular mechanisms for the defective form of the CYP4V2 protein that produce the 
characteristic BCD phenotypes are, as of yet, largely unknown. 
On the other hand, the c.1168C>T mutation in the CYP4V2 gene is located at exon 9. 
This mutation causes a missense mutation (p.R390C) in the CYP4V2 protein. Thus it is 
feasible that this could lead to changes in the cubic structure of the CYP4V2 protein, 
because cysteine is classified into the thiol group leading to disulfide bond. In addition, a 
putative substitution of cysteine for arginine could cause changes in the polarity of the 
CYP4V2 protein at the amino acid 390 position, resulting in structural and/or functional 
disorganization of the protein. In the literature, 6 other mutations have been reported in 
the exon 9 including c.1091–2A>G (Exon9del), c.1157A>C (p.K386T), c.1169G>A 
(p.R390H), c.1187C>T (p.P396L), c.1198C>T (p.R400C), c.1199G>A (p.R400H) [13]. Our 
cases add an additional point mutation to the exon 9. Previous studies regarding the 
relationship between genotypes and phenotypes have revealed that there is no apparent 
rule in phenotypes of BCD in relation to kinds and locations of mutations in the CYP4V2 
gene [13]. Our present case also demonstrated typical features of BCD, supporting 
previous findings. 
Since BCD is thought to be an autosomal recessive disease, heterozygous carriers show 
no clinical symptoms. As the current patient had double heterozygous mutations, and her Case Rep Ophthalmol 2011;2:296–301 
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daughter only had a heterozygous missense mutation of exon 9, this suggests that these 
mutations are located at different alleles. 
Several compound heterozygous mutations have been previously reported for the 
CYP4V2 gene. The mutation of exon 7 (IVS6–8delTCATACAGGTCATCGCG/GC) is 
often detected as one of these. Because the 1168C>T mutation has not previously been 
reported, the present study added a novel 1168C>T (R390C) mutation in the CYP4V2 
gene as a possible causative mutation of BCD. 
Disclosure Statement 







Fig. 1. Slit lamp biomicroscopic findings showing crystalline-like corneal deposits in the superior 
limbal area. 
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Fig. 2. Fundus photograph of the left eye showing numerous crystalline-like deposits and chorioretinal 




Fig. 3. Nucleotide sequence of the CYP4V2 gene at the exon-intron boundary area of the exon 7, 
showing a heterozygous IVS6–8delTCATACAGGTCATCGCG/GC mutation in the patient with BCD. 
Her daughter exhibited a normal sequence similar to the wild-type control. Arrows show positions of 
silent mutations at IVS6–7(C>T) in a control subject and c.810G>T (p.A270A) in the phenotypically 
normal daughter. 
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Fig. 4. Nucleotide sequence of the CYP4V2 gene around nucleotide 1168 in the exon 9, showing the 
heterozygous missense mutations (c.1168C>T) that were found in both the patient and her daughter. 
These mutations resulted in p.R390C. 
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